Protein signatures in human MDA-MB-231 breast cancer cells indicating a more invasive phenotype following knockdown of human endometase/matrilysin-2 by siRNA

Journal of Cancer

Volumn 2, Issue 1, 2011, Pages 165-176

  Lee, Seakwoo ^a,d   Terry, Doris ^b   Hurst, Douglas ^c   Welch, Danny ^c   Sang, Qing Xiang Amy ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b FLORIDA STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c University of Alabama at Birmingham   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer metastasis suppressor 1; Invasion and metastasis; Mass spectrometry; Matrix metalloproteinase (MMP); MMP 26; Proteomics; Putative protein biomarkers

Indexed keywords

ALPHA TUBULIN; BETA ACTIN; BREAST CANCER METASTASIS SUPPRESSOR 1 PROTEIN; CYSTATIN C; GLUCOSE REGULATED PROTEIN 78; HEAT SHOCK PROTEIN 90; LIPOCORTIN 5; MATRIX METALLOPROTEINASE 26; PEROXIREDOXIN 2; SMALL INTERFERING RNA; TROPOMYOSIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PARAMETERS; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

EID: 84873714360     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.2.165     Document Type: Article

References (72)

1. DeClerck YA, Mercurio AM, Stack MS, et al. Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol 2004;164:1131-9.
2. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Curr Opin Cell Biol 2004;16:558-64.
3. Nagase H, Visse R and Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73.
4. Friedl P, Brocker EB. The biology of cell locomotion within three-dimensional extracellular matrix. Cell Mol Life Sci 2000;57:41-64.
5. Wolf K, Mazo I, Leung H, et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J Cell Biol 2003;160:267-77.
6. DeClerck YA. Interactions between tumour cells and stromal cells and proteolytic modification of the extracellular matrix by metalloproteinases in cancer. Eur J Cancer 2000;36:1258-68.
7. Jodele S, Blavier L, Yoon JM and DeClerck YA. Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression. Cancer Metastasis Rev 2006;25:35-43.
8. McCawley LJ, Matrisian LM. Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol 2001;13:534-40.
9. Ahokas K, Skoog T, Suomela S, et al. Matrilysin-2 (matrix met-alloproteinase-26) is upregulated in keratinocytes during wound repair and early skin carcinogenesis. J Invest Dermatol 2005;124:849-56.
10. Gontero P, Banisadr S, Frea B and Brausi M. Metastasis markers in bladder cancer: a review of the literature and clinical considerations. Eur Urol 2004;46:296-311.
11. Lee S, Desai KK, Iczkowski KA, et al. Coordinated peak ex-pression of MMP-26 and TIMP-4 in preinvasive human prostate tumor. Cell Res 2006;16:750-8.
12. Lee S, Park HI and Sang QX. Calcium regulates tertiary structure and enzymatic activity of human endometase/matrilysin-2 and its role in promoting human breast cancer cell invasion. Biochem J 2007;403:31-42.
13. Marchenko GN, Ratnikov BI, Rozanov DV, Godzik A, Deryugina EI and Strongin AY. Characterization of matrix metalloproteinase-26, a novel metalloproteinase widely expressed in cancer cells of epithelial origin. Biochem J 2001;356:705-18.
14. Park HI, Ni J, Gerkema FE, Liu D, Belozerov VE and Sang QX. Identification and characterization of human endometase (Matrix metalloproteinase-26) from endometrial tumor. J Biol Chem 2000;275:20540-4.
15. Uria JA, Lopez-Otin C. Matrilysin-2, a new matrix metalloproteinase expressed in human tumors and showing the minimal domain organization required for secretion, latency, and activity. Cancer Res 2000;60:4745-51.
16. Zhao YG, Xiao AZ, Newcomer RG, et al. Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003;278:15056-64.
17. Savinov AY, Remacle AG, Golubkov VS, et al. Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients. Cancer Res 2006;66:2716-24.
18. Zhao YG, Xiao AZ, Park HI, et al. Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 2004;64:590-8.
19. Hurst DR, Mehta A, Moore BP, et al. Breast cancer metastasis suppressor 1 (BRMS1) is stabilized by the Hsp90 chaperone. Biochem Biophys Res Commun 2006;348:1429-35.
20. Li W, Savinov AY, Rozanov DV, et al. Matrix metalloproteinase-26 is associated with estrogen-dependent malignancies and targets alpha1-antitrypsin serpin. Cancer Res 2004;64:8657-65.
21. Hurst DR, Xie Y, Vaidya KS, et al. Alterations of BRMS1-ARID4A interaction modify gene expression but still suppress metastasis in human breast cancer cells. J Biol Chem 2008;283:7438-44.
22. Phadke PA, Vaidya KS, Nash KT, Hurst DR and Welch DR. BRMS1 suppresses breast cancer experimental metastasis to multiple organs by inhibiting several steps of the metastatic process. Am J Pathol 2008;172:809-17.
23. Samant RS, Seraj MJ, Saunders MM, et al. Analysis of mechanisms underlying BRMS1 suppression of metastasis. Clin Exp Metastasis 2000;18:683-93.
24. Shevde LA, Samant RS, Goldberg SF, et al. Suppression of human melanoma metastasis by the metastasis suppressor gene, BRMS1. Exp Cell Res 2002;273:229-39.
25. Zhang S, Lin QD and Di W. Suppression of human ovarian carcinoma metastasis by the metastasis-suppressor gene, BRMS1. Int J Gynecol Cancer 2006;16:522-31.
26. Smith PW, Liu Y, Siefert SA, Moskaluk CA, Petroni GR and Jones DR. Breast cancer metastasis suppressor 1 (BRMS1) suppresses metastasis and correlates with improved patient survival in non-small cell lung cancer. Cancer Lett 2009;276:196-203.
27. Champine PJ, Michaelson J, Weimer BC, Welch DR and DeWald DB. Microarray analysis reveals potential mechanisms of BRMS1-mediated metastasis suppression. Clin Exp Metastasis 2007;24:551-65.
28. Rivera J, Megias D and Bravo J. Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1. J Proteome Res 2007;6:4006-18.
29. Meehan WJ, Samant RS, Hopper JE, et al. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem 2004;279:1562-9.
30. Samant RS, Clark DW, Fillmore RA, et al. Breast cancer metas-tasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 2007;6:6.
31. Freeman BC, Yamamoto KR. Disassembly of transcriptional regulatory complexes by molecular chaperones. Science 2002;296:2232-5.
32. Lee AS. The glucose-regulated proteins: stress induction and clinical applications. Trends Biochem Sci 2001;26:504-10.
33. Liu H, Bowes RC3rd, van de Water B, Sillence C, Nagelkerke JF and Stevens JL. Endoplasmic reticulum chaperones GRP78 and calreticulin prevent oxidative stress, Ca2+ disturbances, and cell death in renal epithelial cells. J Biol Chem 1997;272:21751-9.
34. Wegele H, Muller L and Buchner J. Hsp70 and Hsp90--a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004;151:1-44.
35. Takayama S, Reed JC and Homma S. Heat-shock proteins as regulators of apoptosis. Oncogene 2003;22:9041-7.
36. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005;5:761-72.
37. Beere HM. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci 2004;117:2641-51.
38. Annamalai B, Liu X, Gopal U and Isaacs JS. Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis. Mol Cancer Res 2009;7:1021-32.
39. Sidera K, Gaitanou M, Stellas D, Matsas R and Patsavoudi E. A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 2008;283:2031-41.
40. Tsutsumi S, Scroggins B, Koga F, et al. A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion. Oncogene 2008;27:2478-87.
41. Woodley DT, Fan J, Cheng CF, et al. Participation of the lipoprotein receptor LRP1 in hypoxia-HSP90alpha autocrine signaling to promote keratinocyte migration. J Cell Sci 2009;122:1495-8.
42. Waza M, Adachi H, Katsuno M, et al. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration. Nat Med 2005;11:1088-95.
43. Jolly C, Morimoto RI. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 2000;92:1564-72.
44. Zuo DS, Dai J, Bo AH, Fan J and Xiao XY. Significance of expression of heat shock protein90alpha in human gastric cancer. World J Gastroenterol 2003;9:2616-8.
45. Fernandez PM, Tabbara SO, Jacobs LK, et al. Overexpression of the glucose-regulated stress gene GRP78 in malignant but not benign human breast lesions. Breast Cancer Res Treat 2000;59:15-26.
46. Little E, Ramakrishnan M, Roy B, Gazit G and Lee AS. The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit Rev Eukaryot Gene Expr 1994;4:1-18.
47. Shuda M, Kondoh N, Imazeki N, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 2003;38:605-14.
48. Takashima M, Kuramitsu Y, Yokoyama Y, et al. Proteomic profiling of heat shock protein 70 family members as biomarkers for hepatitis C virus-related hepatocellular carcinoma. Proteomics 2003;3:2487-93.
49. Lehtonen ST, Markkanen PM, Peltoniemi M, Kang SW and Kinnula VL. Variable overoxidation of peroxiredoxins in human lung cells in severe oxidative stress. Am J Physiol Lung Cell Mol Physiol 2005;288:L997-1001.
50. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y. Peroxiredoxins in breast carcinoma. Clin Cancer Res 2003;9:3418-24.
51. Kim H, Lee TH, Park ES, et al. Role of peroxiredoxins in regulating intracellular hydrogen peroxide and hydrogen peroxide-induced apoptosis in thyroid cells. J Biol Chem 2000;275:18266-70.
52. Hayashi E, Kuramitsu Y, Okada F, et al. Proteomic profiling for cancer progression: Differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics 2005;5:1024-32.
53. Kinnula VL, Lehtonen S, Sormunen R, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J Pathol 2002;196:316-23.
54. Lehtonen ST, Svensk AM, Soini Y, et al. Peroxiredoxins, a novel protein family in lung cancer. Int J Cancer 2004;111:514-21.
55. Kirsch T, Nah HD, Demuth DR, et al. Annexin V-mediated calcium flux across membranes is dependent on the lipid composition: implications for cartilage mineralization. Biochemistry 1997;36:3359-67.
56. Wang W, Xu J and Kirsch T. Annexin V and terminal differentiation of growth plate chondrocytes. Exp Cell Res 2005;305:156-65.
57. Mulla A, Christian HC, Solito E, Mendoza N, Morris JF and Buckingham JC. Expression, subcellular localization and phosphorylation status of annexins 1 and 5 in human pituitary adenomas and a growth hormone-secreting carcinoma. Clin Endocrinol (Oxf) 2004;60:107-19.
58. Cooper JA. Actin dynamics: tropomyosin provides stability. Curr Biol 2002;12:R523-5.
59. Marston S, Burton D, Copeland O, et al. Structural interactions between actin, tropomyosin, caldesmon and calcium binding protein and the regulation of smooth muscle thin filaments. Acta Physiol Scand 1998;164:401-14.
60. O'Neill GM. The coordination between actin filaments and adhesion in mesenchymal migration. Cell Adh Migr 2009;3:355-7.
61. Miyado K, Kimura M and Taniguchi S. Decreased expression of a single tropomyosin isoform, TM5/TM30nm, results in reduction in motility of highly metastatic B16-F10 mouse melanoma cells. Biochem Biophys Res Commun 1996;225:427-35.
62. Lu QY, Jin YS, Pantuck A, et al. Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic model. Clin Cancer Res 2005;11:1675-83.
63. Taniguchi S. Suppression of cancer phenotypes through a multifunctional actin-binding protein, calponin, that attacks cancer cells and simultaneously protects the host from invasion. Cancer Sci 2005;96:738-46.
64. Nowak D, Skwarek-Maruszewska A, Zemanek-Zboch M and Malicka-Blaszkiewicz M. Beta-actin in human colon adenocarcinoma cell lines with different metastatic potential. Acta Biochim Pol 2005;52:461-8.
65. Rao S, Aberg F, Nieves E, Band Horwitz S and Orr GA. Identification by mass spectrometry of a new alpha-tubulin isotype expressed in human breast and lung carcinoma cell lines. Biochemistry 2001;40:2096-103.
66. Sharp DJ, Rogers GC and Scholey JM. Microtubule motors in mitosis. Nature 2000;407:41-7.
67. Idriss HT. Three steps to cancer: how phosphorylation of tubulin, tubulin tyrosine ligase and P-glycoprotein may generate and sustain cancer. Cancer Chemother Pharmacol 2004;54:101-4.
68. Mialhe A, Lafanechere L, Treilleux I, et al. Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Res 2001;61:5024-7.
69. Kato T, Imatani T, Minaguchi K, Saitoh E and Okuda K. Sali-vary cystatins induce interleukin-6 expression via cell surface molecules in human gingival fibroblasts. Mol Immunol 2002;39:423-30.
70. Sabatini LM, Warner TF, Saitoh E and Azen EA. Tissue distribution of RNAs for cystatins, histatins, statherin, and proline-rich salivary proteins in humans and macaques. J Dent Res 1989;68:1138-45.
71. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004;6:507-14.
72. Strongin AY. Mislocalization and unconventional functions of cellular MMPs in cancer. Cancer Metastasis Rev 2006;25:87-98.